Condition

To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

ClinicalTrials.gov condition label

Clinical trials1

Recruiting0

Common interventions1

Lead sponsors shown1

Clinical trials

1 shown

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast CancerNCT05802342 · 2023-04-20

UNKNOWN

Common interventions

Monosialotetrahexose ganglioside sodium injectionDRUG1

Leading sponsors

Qilu Pharmaceutical Co., Ltd.1

Trial status mix

UNKNOWN1

Phase mix

PHASE21

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.